Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.54 |
| ▸ | ABL1 | P00519 | 17/20 | 0.54 |
| ▸ | SRC | P12931 | 17/20 | 0.54 |
| ▸ | EGFR | P00533 | 16/20 | 0.54 |
| ▸ | HCK | P08631 | 16/20 | 0.54 |
| ▸ | KDR | P35968 | 16/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 16/20 | 0.54 |
| ▸ | MTOR | P42345 | 16/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 16/20 | 0.54 |
| ▸ | PRKDC | P78527 | 16/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 15/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21467053 | 0.87 | PIK3CG (0.52) | PIK3CDPIK3CAPIK3CGABL1SRC | |
| SCHEMBL11928101 | 0.84 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CGABL1SRC | |
| SCHEMBL16665803 | 0.84 | PIK3CD (0.57) | PIK3CDPIK3CAPIK3CGABL1SRC | |
| SCHEMBL23917236 | 0.84 | PIK3CD (0.39) | PIK3CDPIK3CAPIK3CGABL1SRC | |
| SCHEMBL9010 | 0.81 | PIK3CG (0.54) | PIK3CDPIK3CAPIK3CGABL1SRC | |
| SCHEMBL11214 | 0.81 | DYRK1A (0.48) | PIK3CDPIK3CAPIK3CGABL1SRC | |
| SCHEMBL3715031 | 0.80 | SRC (0.57) | PIK3CDPIK3CAPIK3CGABL1SRC | |
| SCHEMBL11325 | 0.80 | PIK3CG (0.49) | PIK3CDPIK3CAPIK3CGABL1SRC | |
| SCHEMBL21467103 | 0.78 | PIK3CD (0.40) | PIK3CDPIK3CAPIK3CGABL1SRC | |
| SCHEMBL20748491 | 0.78 | PIK3CG (0.54) | PIK3CDPIK3CAPIK3CGABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | PIK3CD 2/4885PIK3CA 4/4885PIK3CG 15/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PIK3CD 103/4885PIK3CA 144/4885PIK3CG 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.